Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
07/01/2013 | 01:27pm CET
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
12/08 TEVA PHARMACEUTICAL INDUSTRIES : probes alleged Romanian bribes
12/08 DEADLINE ALERT : Brower Piven Alerts Shareholders Of Approaching Deadline In Cla..
12/07 TEVA PHARMACEUTICAL INDUSTRIES : to Present at the Citi 2016 Global Healthcare C..
12/07 TEVA’S PHARMACEUTICAL INDUSTRI : TEVA) End-Of-Year Switch Of Generics CEO ..
12/07 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Blog Coverage Teva Reports Positive Outco..
12/07 TEVA PHARMACEUTICAL INDUSTRIES : Pharma Appoints New Global Generic Medicines Gr..
12/07 TEVA PHARMACEUTICAL INDUSTRIES : Appoints Dipankar Bhattacharjee as President an..
12/07 TEVA PHARMACEUTICAL INDUSTRIES : Receives Positive Outcome for COPAXONE Label in..
12/07 TEVA PHARMACEUTICAL INDUSTRIES : Dipankar bhattacharjee to head teva global oper..
12/06 TEVA PHARMACEUTICAL INDUSTRIES : Receives Positive Outcome for COPAXONE® Label i..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 Healthcare bounces back from Trump tantrum
12/09 They're Definitely High On Something
12/08 Orexo to appeal Zubsolv patent ruling
12/06 Teva's Near-7x Price-To-Earnings Multiple
12/06 Investors not liking departure of Teva's Olafsson; shares down 4% premarket
Financials ($)
Sales 2016 22 197 M
EBIT 2016 7 195 M
Net income 2016 3 321 M
Debt 2016 25 826 M
Yield 2016 3,29%
P/E ratio 2016 8,11
P/E ratio 2017 6,69
EV / Sales 2016 2,79x
EV / Sales 2017 2,20x
Capitalization 36 129 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 59,2 $
Spread / Average Target 67%
Consensus details
EPS Revisions
More Estimates Revisions
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.29%301 952
ROCHE HOLDING LTD.-17.58%189 184
PFIZER INC.-4.15%187 755
NOVARTIS AG-18.49%178 671
MERCK & CO., INC.15.92%165 759
More Results